Skip to search formSkip to main contentSkip to account menu

0.8 ML Filgrastim 0.6 MG/ML Prefilled Syringe [Neupogen]

Known as: FILGRASTIM 480 ug in 0.8 mL SUBCUTANEOUS INJECTION, SOLUTION [NEUPOGEN], Neupogen 480 MCG per 0.8 ML Prefilled Syringe, 0.8 ML Neupogen 0.6 MG/ML Prefilled Syringe 
National Institutes of Health

Related topics

Related topics

9 relations
Acetic AcidFilgrastimNeupogenPolysorbate 80

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Quality Comparison of Biosimilar and Copy Filgrastim Products with the Innovator Product
Filgrastim, a recombinant human granulocyte-colony stimulating factor, is widely used to treat congenital and acquired… 
2017
2017
Biosimilar filgrastim (leucostim®) have similar efficacy in steady-state hematopoietic progenitor cell mobilization compared to original filgrastim (neupogen®) and lenograstim (granocyte®): A…
2016
2016
Mobilization of hematopoietic progenitor cells from allogeneic healthy donors using a new biosimilar G‐CSF (Zarzio®)
Peripheral blood progenitor cells (PBPCs) have become the major source of hematopoietic progenitor cells for allogeneic… 
2015
2015
The Effect of Radiation Dose and Variation in Neupogen® Initiation Schedule on the Mitigation of Myelosuppression during the Concomitant GI-ARS and H-ARS in a Nonhuman Primate Model of High-dose…
AbstractA nonhuman primate (NHP) model of acute high-dose, partial-body irradiation with 5% bone marrow (PBI/BM5) sparing was… 
2015
2015
Zarzio®, biosimilar of filgrastim, in prophylaxis of chemotherapy-induced neutropenia in routine practice: a French prospective multicentric study
PurposeChemotherapy-induced neutropenia is a serious and potentially life-threatening consequence of cancer treatment… 
2013
2013
The comparison of Filgrastim (Neupogen®), biosimilar filgrastim (Leucostim®) and Lenograstim (Granocyte®) as a first line peripheral blood stem cell mobilization strategy in autologous hematopoieitic…
Highly Cited
2012
Highly Cited
2012
Comparative cost-efficiency across the European G5 countries of various regimens of filgrastim, biosimilar filgrastim, and pegfilgrastim to reduce the incidence of chemotherapy-induced febrile…
Objectives: This cost-efficiency analysis of the granulocyte colony-stimulating factors (G-CSF) filgrastim (originator Neupogen… 
2012
2012
Pharmacokinetic and Pharmacodynamic Profile of New Biosimilar Filgrastim XM02 Equivalent to Marketed Filgrastim Neupogen®
ObjectiveFilgrastim XM02 is a biosimilar non-glycosylated recombinant methionyl form of human granulocyte colony-stimulating… 
Highly Cited
2010
Highly Cited
2010
Physicochemical and Biologic Comparability of a Biosimilar Granulocyte Colony-Stimulating Factor with its Reference Product
BackgroundDevelopment of biosimilars requires physicochemical and biologic characterization to show comparability with a… 
Highly Cited
2008
Highly Cited
2008
XM02 is superior to placebo and equivalent to Neupogen™ in reducing the duration of severe neutropenia and the incidence of febrile neutropenia in cycle 1 in breast cancer patients receiving…
BackgroundRecombinant granulocyte colony-stimulating factors (G-CSFs) such as Filgrastim are used to treat chemotherapy-induced… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)